| TABLE OF CONTENTS | |||||||||||||||||||||||||||||||||||||
| March 2013 Volume 10 Number 3 | |||||||||||||||||||||||||||||||||||||
In this issue
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| NEWS AND VIEWS | Top | ||||||||||||||||||||||||||||||||||||
| Prostate cancer: Proton therapy-revolutionary advance or diminishing returns? Phillip J. Gray & Jason A. Efstathiou Published online: 12 February 2013 p128 | doi:10.1038/nrurol.2013.16 Proton therapy is a promising but costly technology for the treatment of prostate cancer. Although compelling evidence has shown proton therapy to be safe and effective for cancer treatment, comparative randomized data are needed to clarify its role and value in future practice. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| Prostate cancer: Interpreting cost-utility analysis of prostate cancer treatment James B. Yu Published online: 12 February 2013 p129 | doi:10.1038/nrurol.2013.17 Measuring the cost and comparative effectiveness of different treatments for localized prostate cancer is difficult. A recent paper by Cooperberg and colleagues has attempted to address this difficulty, but, although some valuable insights are obtained through their skillful work, its applicability is limited. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| Prostate cancer: Benefit and safety of adjuvant radiation therapy Beatrice Detti & Daniele Scartoni Published online: 22 January 2013 p131 | doi:10.1038/nrurol.2012.260 10-year data from the European Organisation for Research and Treatment of Cancer trial 22911 have been published, reigniting the debate regarding postoperative radiotherapy for prostate cancer. These data show that adjuvant radiotherapy significantly improves biochemical progression-free survival and local control compared with a 'wait-and-see' policy, supporting the 5-year follow-up data. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| Prostate cancer: Are urologists ready to manage castration-resistant disease? Henry H. Woo Published online: 19 February 2013 p133 | doi:10.1038/nrurol.2013.25 The progression of prostate cancer to castration-resistant disease usually marks the transition of patient care from urologist to medical oncologist. The demonstration that a new generation of oral agents, such as abiraterone acetate, can be administered before chemotherapy suggests the dynamics of advanced prostate cancer care are about to change. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| REVIEWS | Top | ||||||||||||||||||||||||||||||||||||
| Multiparametric ultrasonography of the testicles Tobias De Zordo, Daniel Stronegger, Leo Pallwein-Prettner, Chris J. Harvey, Germar Pinggera, Werner Jaschke, Friedrich Aigner & Ferdinand Frauscher Published online: 22 January 2013 p135 | doi:10.1038/nrurol.2012.255 Advances in ultrasonography technology have produced new innovative techniques in imaging of the scrotum that can be useful when diagnosing diseases and disorders of the testicles. Consequently, the standard approach to accurate diagnosis should rely on multiparametric ultrasonography techniques, rather than just one or two techniques in isolation. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| Proposed mechanisms of action for prostate cancer vaccines Sean M. Geary, Caitlin D. Lemke, David M. Lubaroff & Aliasger K. Salem Published online: 12 February 2013 p149 | doi:10.1038/nrurol.2013.8 In this Review, Geary and colleagues discuss the potential mechanisms of action for all prostate cancer vaccines that trigger cytotoxic-T-lymphocyte-mediated responses and have reached clinical trials. They consider ways in which key immune events are likely to affect the efficacy of each vaccine and consider how information regarding these potential mechanisms can be exploited for future combinatorial treatments. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| Safety in the operating theatre-a transition to systems-based care Thomas G. Weiser, Michael P. Porter & Ronald V. Maier Published online: 19 February 2013 p161 | doi:10.1038/nrurol.2013.13 In this Review, Weiser and colleagues outline a number of parameters for evaluating the quality of surgical care and explore some systems-based interventions that aim to improve teamwork, communication, and the evaluation of safety and outcomes, with particular focus on urological procedures. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| Artificial neural networks and prostate cancer-tools for diagnosis and management Xinhai Hu, Henning Cammann, Hellmuth-A. Meyer, Kurt Miller, Klaus Jung & Carsten Stephan Published online: 12 February 2013 p174 | doi:10.1038/nrurol.2013.9 In this Review, the authors describe artificial neural networks (ANNs), which are mathematical tools used in medicine for cancer diagnosis, staging and recurrence prediction. With an emphasis on prostate cancer, they detail how ANNs offer a number of advantages as clinical decision-making tools, and describe the strengths and weaknesses of various models and input parameters. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| CORRESPONDENCE | Top | ||||||||||||||||||||||||||||||||||||
| C-reactive protein in bladder cancer: where do we stand? Georgios Gakis & Arnulf Stenzl Published online: 05 February 2013 p182 | doi:10.1038/nrurol.2011.145-c1 Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| REPLY | Top | ||||||||||||||||||||||||||||||||||||
| Author's reply: CRP kinetics could be prognostic predictors in urothelial cancer Kazutaka Saito & Kazunori Kihara Published online: 05 February 2013 p182 | doi:10.1038/nrurol.2011.145-c2 Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| *Journal Citation Reports, Thomson, 2011. Nature Reviews Urology was previously published as Nature Clinical Practice Urology. |
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. |
No comments:
Post a Comment
Keep a civil tongue.